Roche, to counter biosimilars, sees launches, data on 8 new drugs by 2018
[ZURICH] Roche is planning launches or pivotal data for up to eight new medicines in the next three years as it seeks to fend off competition from copycat versions of its older drugs.
The Swiss drugmaker expects up to seven major results from clinical trials on new drugs or extensions for existing medicines through 2017.
That would add to seven clinical study results released in 2015, Roche said Thursday ahead of an event for investors where it was set to focus on research and development, its drug pipeline and strategy.
Roche is banking on a host of new drugs, including immune-system boosting atezolizumab for bladder and lung cancer and ocrelizumab for multiple sclerosis, to help it fend off competition from biosimilar versions of its older drugs starting in 2017 as their patents expire.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO